Coloplast — M&A Activity 2018

Jan 10, 2018

Coloplast

Ostomy Care

Continence Care

Wound & Skin Care

Urology Care

Announcement No. 01/2018

10 January 2018

Coloplast completes acquisition of SAS Lilial

Coloplast has now completed the acquisition of Lilial.

All terms remain as stated in Coloplast's stock exchange announcement no. 13/2017 regarding the acquisition of Lilial and Coloplast confirms the previously stated guidance for the financial year 2017/18:

• The organic revenue growth guidance of ~7% is unchanged. The growth in DKK of 5-6% based on spot rates as of 31 October 2017 is expected to be ~1%-points higher.
• The EBIT margin guidance of 31-32% in constant exchange rates and about 31% in DKK is unchanged.

The long-term guidance for the LEAD 20 strategy period until fiscal year-end 2019/20 of 7-9% organic growth p.a. and an EBIT margin of more than 30% in constant currencies is unchanged.

For more information on Lilial please refer to www.lilial.fr.

Lars Rasmussen

President & CEO

Coloplast A/S

Holtedam 1

3050 Humlebæk

Denmark

Tel: +45 4911 1111

www.coloplast.com

CVR-nr. 69749917

1/2

---

Coloplast
Ostomy Care
Continence Care
Wound & Skin Care
Urology Care

For further information, please contact

Investors and analysts
Anders Lonning-Skovgaard
Executive Vice President, CFO
Tel. 4911 1111

Ellen Bjurgert
Director, Investor Relations
Tel. 4911 1800 / 4911 3376
E-mail dkebj@coloplast.com

Press and the media
Lina Danstrup
Senior Media Relations Manager
Tel. 4911 2607
E-mail dklina@coloplast.com

Website
www.coloplast.com

Address
Coloplast A/S
Holtedam 1
DK-3050 Humlebæk
Denmark
CVR NR. 69749917

This announcement is available in a Danish and an English-language version. In the event of any discrepancies, the Danish version shall prevail.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2018-01 All rights reserved.
Coloplast A/S, 3050 Humlebæk, Denmark.

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare.

Our business includes Ostomy Care, Urology Care, Continence Care and Wound and Skin Care. We operate globally and employ about 11,000 people.

2/2